<DOC>
	<DOCNO>NCT02329106</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy irreversible electroportion unresectable liver cancer close diaphragmatic dome .</brief_summary>
	<brief_title>Percutaneous Irreversible Electroportion Unresectable Liver Cancer Close Diaphragmatic Dome</brief_title>
	<detailed_description>Single-arm pilot clinical trial . Patients subject irreversible electroporation ( IRE ) sole treatment liver cancer close diaphragmatic dome . This pilot study design study feasibility safety treatment alternative therapeutic IRE treatment neoplastic nodule liver , particular reference close diaphragmatic dome , current therapeutic arsenal inadequate counter-indicated . To perform IRE procedure IRE NanoKnife™ System ( AngioDynamics ) use .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Liver cancer diagnose positive biopsy noninvasive criterion , Tumors diaphragm ＜1 cm suitable surgical resection transplantation , least one , less equal 3 tumor , tumour ( ) identify , tumor must ≤ 5 cm diameter , ChildPugh class A , B Eastern Cooperative Oncology Group ( ECOG ) score 01 , prothrombin time ratio &gt; 50 % , platelet count &gt; 80x109/L , ability patient stop anticoagulant antiplatelet therapy seven day prior seven day post NanoKnife procedure , able comprehend willing sign write informed consent form ( ICF ) , life expectancy least 3 month . liver cancer develop already transplant liver , cardiac insufficiency , ongoing coronary artery disease arrhythmia , active implant device ( eg Pacemaker ) , woman pregnant woman childbearing potential use acceptable method contraception , receive treatment investigational agent/ procedure within 30 day prior treatment NanoKnife™ LEDC System , opinion Investigator unable comply visit schedule protocol evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>